Cargando…
Without 1α-hydroxylation, the gene expression profile of 25(OH)D(3) treatment overlaps deeply with that of 1,25(OH)(2)D(3) in prostate cancer cells
Recently, the antiproliferative action of 1,25(OH)(2)D(3) (1,25D3), an active metabolite of vitamin D(3), in the management of prostate cancer has been argued rigorously. In this study, we found that at a physiological concentration, 25(OH)D(3) (25D3), the precursor of 1,25D3 and an inactive form of...
Autores principales: | Susa, Takao, Iizuka, Masayoshi, Okinaga, Hiroko, Tamamori-Adachi, Mimi, Okazaki, Tomoki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998076/ https://www.ncbi.nlm.nih.gov/pubmed/29899561 http://dx.doi.org/10.1038/s41598-018-27441-x |
Ejemplares similares
-
Association among plasma 1,25(OH)(2)D, ratio of 1,25(OH)(2)D to 25(OH)D, and prostate cancer aggressiveness
por: Ramakrishnan, Swathi, et al.
Publicado: (2019) -
Intrinsic ubiquitin E3 ligase activity of histone acetyltransferase Hbo1 for estrogen receptor α
por: IIZUKA, Masayoshi, et al.
Publicado: (2017) -
Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
por: Vlot, Mariska C, et al.
Publicado: (2019) -
Antidepressants differentially related to 1,25-(OH)(2) vitamin D(3) and 25-(OH) vitamin D(3) in late-life depression
por: Oude Voshaar, R C, et al.
Publicado: (2014) -
Does Sevelamer Hydrochloride (Renagel) Influence 25(Oh)D3 and 1,25(Oh)2D3 Level in Haemodialysis Patients?
por: Strózecki, Pawel, et al.
Publicado: (2005)